USANA Health Sciences Inc (USNA) SEC filings

USNANYSEMedicinal Chemicals & Botanical ProductsFiscal year ends January 3

Financials through Q3 FY2026, quarter ended Oct 3, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3058% below fair value

$13.24+0.51 (+4.01%)

Close on Nov 13, 2026Market cap $244.63MP/E –Yield –

SEC filings

40 of USANA Health Sciences's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Oct 3, 2026	Nov 12, 2026	SEC EDGAR
Current report	8-K	Nov 3, 2026	Nov 3, 2026	SEC EDGAR
Current report	8-K	Oct 5, 2026	Oct 5, 2026	SEC EDGAR
Quarterly report	10-Q	Jul 4, 2026	Aug 13, 2026	SEC EDGAR
Current report	8-K	Aug 4, 2026	Aug 4, 2026	SEC EDGAR
Current report	8-K	May 20, 2026	May 20, 2026	SEC EDGAR
Quarterly report	10-Q	Apr 4, 2026	May 12, 2026	SEC EDGAR
Current report	8-K	May 5, 2026	May 5, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jan 3, 2026	Apr 7, 2026	SEC EDGAR
Annual report	10-K	Jan 3, 2026	Mar 16, 2026	SEC EDGAR
Current report	8-K	Feb 17, 2026	Feb 18, 2026	SEC EDGAR
Current report	8-K	Jan 12, 2026	Jan 12, 2026	SEC EDGAR
Current report	8-K	Jan 8, 2026	Jan 8, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 27, 2025	Nov 5, 2025	SEC EDGAR
Current report	8-K	Oct 22, 2025	Oct 22, 2025	SEC EDGAR
Current report	8-K	Oct 9, 2025	Oct 9, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 28, 2025	Aug 5, 2025	SEC EDGAR
Current report	8-K	Jul 22, 2025	Jul 22, 2025	SEC EDGAR
Current report	8-K	Jun 27, 2025	Jul 1, 2025	SEC EDGAR
Current report	8-K	May 19, 2025	May 20, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 29, 2025	May 6, 2025	SEC EDGAR
Current report	8-K	Apr 22, 2025	Apr 22, 2025	SEC EDGAR
Proxy statement	DEF 14A	Dec 28, 2024	Apr 4, 2025	SEC EDGAR
Annual report	10-K	Dec 28, 2024	Mar 12, 2025	SEC EDGAR
Current report	8-K	Feb 25, 2025	Feb 25, 2025	SEC EDGAR
Current report	8-K	Dec 23, 2024	Dec 23, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 28, 2024	Nov 5, 2024	SEC EDGAR
Current report	8-K	Oct 22, 2024	Oct 22, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 29, 2024	Aug 6, 2024	SEC EDGAR
Current report	8-K	Jul 23, 2024	Jul 23, 2024	SEC EDGAR
Current report	8-K	May 6, 2024	May 7, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 30, 2024	May 7, 2024	SEC EDGAR
Current report	8-K	Apr 30, 2024	Apr 30, 2024	SEC EDGAR
Proxy statement	DEF 14A	Dec 30, 2023	Mar 22, 2024	SEC EDGAR
Annual report	10-K	Dec 30, 2023	Feb 27, 2024	SEC EDGAR
Current report	8-K	Feb 6, 2024	Feb 6, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2023	Nov 7, 2023	SEC EDGAR
Current report	8-K	Oct 24, 2023	Oct 24, 2023	SEC EDGAR
Quarterly report	10-Q	Jul 1, 2023	Aug 8, 2023	SEC EDGAR
Current report	8-K	Jul 25, 2023	Jul 25, 2023	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in USANA Health Sciences's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Nov 23, 2016
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is USNA.

Compare: USNA vs NATR · USNA vs TLRY · USNA vs MTEX · USNA vs CRLBF · USNA vs PBH

Revenue growth-0.8% · median 3.2%

Gross margin77.3% · median 62.8%

Operating margin-0.4% · median 3.1%

Net margin-2.3% · median 1.3%

Company	Revenue	Growth
PBH	$1.17B	+5.1%
TLRY	$963.10M	+15.9%
USNA	$905.58M	-0.8%
NATR	$480.29M	+1.2%
MTEX	$103.07M	-6.6%
CRLBF	–	–

Company

Next earnings (est.): Feb 17, 2027, after close
Exchange: NYSE
Industry: Medicinal Chemicals & Botanical Products
Fiscal year ends: January 3
Employees: 1,570
Held by institutions: 66.2%
Auditor: KPMG LLP
SEC CIK: 896264

Advertisement
300 × 250

See a number that looks wrong?